



ASX / Media Release

24 April 2026

Invex to Expand Preclinical Research Program

Invex Therapeutics Limited (**Invex**, **ASX:IXC**, or **the Company**) is pleased to announce the commencement of an expanded preclinical research program, with Tessara Therapeutics (Tessara) evaluating Exenatide and other current GLP-1 receptor agonists, including novel combination regimens, in Tessara's human induced pluripotent stem cell (iPSC)-derived three-dimensional Alzheimer's disease model, ADBrain™.

Background and Rationale

The program builds directly on prior work conducted in the ADBrain™ platform in which exenatide demonstrated statistically significant improvements across multiple pathologically relevant biomarkers of Alzheimer's disease (AD).

Notably, Exenatide demonstrated a potential neuroprotective effect against ferroptosis — an iron-dependent oxidative cell death pathway increasingly implicated in AD neurodegeneration — representing a mechanistically differentiated finding relative to current standard-of-care therapies.

Program Design

The expanded study is designed to:

1. **Benchmark Exenatide against a current GLP-1 agonist** enabling direct head-to-head comparisons of two clinically active GLP-1 receptor agonists;
2. **Evaluate combination regimens** of Exenatide and a current GLP-1 agonist against approved AD symptomatic treatments exploring additive or synergistic therapeutic effects over current standards of care; and
3. **Evaluate novel combination regimens** of Exenatide and a current GLP-1 agonist with naturally-recurring factors that demonstrate synergistic improvements in AD phenotype.

Tolerability and efficacy assessments will utilise Tessara's validated assay suite measuring cytotoxicity, cell viability and ferroptosis, supplemented by assays aimed to characterise the mechanistic signature of each agent and combination.

Outlook

The Company will provide further updates on the progress and results of this program in accordance with its continuous disclosure obligations under ASX Listing Rule 3.1.

- ENDS -

This release dated 24 April 2026 has been authorised for lodgement to ASX by the Board of Invex Therapeutics Ltd.

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.